N-Acetylcysteine as Adjuvant Therapy for COVID-19
N-Acetylcysteine as Adjuvant Therapy for COVID-19 - A Perspective on the Current State of the Evidence
The looming severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a long-lasting pandemic of coronavirus disease 2019 (COVID-19) around the globe with substantial morbidity and mortality. N-acetylcysteine, being a nutraceutical precursor of an important antioxidant glutathione, can perform several biological functions in mammals and microbes. It has consequently garnered a growing interest as a potential adjunctive therapy for coronavirus disease. Here, we review evidence concerning the effects of N-acetylcysteine in respiratory viral infections based on currently available in vitro, in vivo, and human clinical investigations. The repurposing of a known drug such as N-acetylcysteine may significantly hasten the deployment of a novel approach for COVID-19. Since the drug candidate has already been translated into the clinic for several decades, its established pharmacological properties and safety and side-effect profiles expedite preclinical and clinical assessment for the treatment of COVID-19. In vitro data have depicted that N-acetylcysteine increases antioxidant capacity, interferes with virus replication, and suppresses expression of pro-inflammatory cytokines in cells infected with influenza viruses or respiratory syncytial virus. Furthermore, findings from in vivo studies have displayed that, by virtue of immune modulation and anti-inflammatory mechanism, N-acetylcysteine reduces the mortality rate in influenza-infected mice animal models. The promising in vitro and in vivo results have prompted the initiation of human subject research for the treatment of COVID-19, including severe pneumonia and acute respiratory distress syndrome. Albeit some evidence of benefits has been observed in clinical outcomes of patients, precision nanoparticle design of N-acetylcysteine may allow for greater therapeutic efficacy.
Keywords: N-acetylcysteine; SARS-CoV-2; COVID-19; T lymphocytes; anti-inflammatory response; antioxidant; antiviral effect; clinical translation; coronavirus; engineering nanoparticles; glutathione; immune modulating activity; repurposing approved drugs; respiratory viral diseases; virus infected cells.
© 2021 Wong et al.
Conflict of interest statement
The authors declared that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2.
Poe FL, Corn J.Med Hypotheses. 2020 Oct;143:109862. doi: 10.1016/j.mehy.2020.109862. Epub 2020 May 30.PMID: 32504923 Free PMC article.
- [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
Plaze M, Attali D, Petit AC, Blatzer M, Simon-Loriere E, Vinckier F, Cachia A, Chrétien F, Gaillard R.Encephale. 2020 Jun;46(3S):S35-S39. doi: 10.1016/j.encep.2020.04.010. Epub 2020 Apr 29.PMID: 32387014 Free PMC article. French.
- N-acetylcysteine and coronavirus disease 2019: May it work as a beneficial preventive and adjuvant therapy? A comprehensive review study.
Atefi N, Behrangi E, Mozafarpoor S, Seirafianpour F, Peighambari S, Goodarzi A.J Res Med Sci. 2020 Nov 26;25:109. doi: 10.4103/jrms.JRMS_777_20. eCollection 2020.PMID: 33824674 Free PMC article. Review.
Cited by 3 articles
- Preliminary Findings on the Association of the Lipid Peroxidation Product 4-Hydroxynonenal with the Lethal Outcome of Aggressive COVID-19.
Žarković N, Orehovec B, Milković L, Baršić B, Tatzber F, Wonisch W, Tarle M, Kmet M, Mataić A, Jakovčević A, Vuković T, Talić D, Waeg G, Lukšić I, Skrzydlewska E, Žarković K.Antioxidants (Basel). 2021 Aug 25;10(9):1341. doi: 10.3390/antiox10091341.PMID: 34572973 Free PMC article.
- Changes in Glycolytic Pathway in SARS-COV 2 Infection and Their Importance in Understanding the Severity of COVID-19.
Santos AF, Póvoa P, Paixão P, Mendonça A, Taborda-Barata L.Front Chem. 2021 Sep 10;9:685196. doi: 10.3389/fchem.2021.685196. eCollection 2021.PMID: 34568275 Free PMC article. Review.
- Use of Thiols in the Treatment of COVID-19: Current Evidence.
Cazzola M, Rogliani P, Salvi SS, Ora J, Matera MG.Lung. 2021 Aug;199(4):335-343. doi: 10.1007/s00408-021-00465-3. Epub 2021 Aug 27.PMID: 34448938 Free PMC article. Review.